החברה עולה בעקבות דו"חות אבל המספרים הם לא המהות
חברת IGM Biosciences, Inc. מפרסמת דו"חות ומחיר המניה שלה (IGMS) מכפיל את עצמו - לא בגלל הדו"ח אלא בגלל הפרסום הנלווה לדו"ח
– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones –
– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones –
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.